Guideline Summary for Initiation and Management of Iron‑Deficiency Anemia

Immediate Initiation of Iron Therapy

Oral Iron Therapy

First‑Line Regimen

Enhancing Absorption

Dosing Strategies for Tolerability

Intravenous Iron – Indications and Preferred Formulations

When to Prefer IV Iron

• Prior bariatric surgery that bypasses duodenal absorption. 2
• Active inflammatory bowel disease with compromised mucosal absorption. 3
• Celiac disease with malabsorption. 2

Preferred IV Formulations

Monitoring and Duration of Therapy

Additional Considerations

Management of Iron Deficiency Anemia in Patients with Confirmed IgE‑Mediated Allergy to Monoferric

Assessment of the Allergic Reaction

• Distinguish true IgE‑mediated anaphylaxis (airway compromise, mucosal swelling, systemic hypotension, wheezing, stridor, or gastrointestinal pain) from CARPA (flushing, myalgias/arthralgias, back pain, or chest pressure without hypotension or airway symptoms) in patients receiving IV iron 4.

• CARPA reactions are self‑limited, do not represent a true allergy, can occur with any IV iron formulation, and do not preclude subsequent use of a different IV iron product 4.

Alternative Intravenous Iron Formulations

• For patients with a confirmed IgE‑mediated allergy to Monoferric (ferric derisomaltose), switch to an IV iron product that has a distinct carbohydrate‑shell chemistry—such as iron sucrose, ferric gluconate, or ferumoxytol—because cross‑reactivity is considered unlikely 4.

• Ferric gluconate and iron sucrose release larger amounts of labile free iron, necessitating lower doses per infusion and more frequent administrations compared with high‑dose formulations 4.

Safety Monitoring After IV Iron

• Monitor patients for treatment‑emergent hypophosphatemia following any IV iron administration 4.

Extended Iron Therapy After Hemoglobin Normalization

Duration of Therapy

• Continuing oral iron supplementation for 2–3 months after hemoglobin has returned to normal helps rebuild depleted iron reserves and prevents rapid recurrence of anemia. 5

Monitoring Iron Repletion

• Ferritin levels should be measured during the extended treatment period; a rising ferritin concentration indicates successful replenishment of body iron stores. 5

Dosing Strategy

• An every‑other‑day dosing schedule (e.g., ferrous sulfate, fumarate, or gluconate) provides gastrointestinal tolerance comparable to daily dosing while maintaining similar iron absorption. 5

Adjunctive Therapy

• Co‑administration of vitamin C with the iron preparation, when used in the initial regimen, should be continued to enhance intestinal iron absorption. 5

Evaluation of Underlying Cause

• Before stopping iron therapy completely, clinicians should confirm that the underlying cause of iron deficiency has been fully investigated and appropriately managed (e.g., menstrual loss, malabsorption, chronic bleeding). 5